Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087477 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of Pivanex in Patients With Malignant Melanoma
A Phase 1 study, sponsored by Titan Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00087477 is a Phase 1 study that was terminated before completion, run by Titan Pharmaceuticals. The registered enrollment target is 14 participants.
The verdict
NCT00087477, a Phase 1 study, was terminated before completion, sponsored by Titan Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This pilot study will assess the safety and efficacy of Pivanex alone in patients with malignant melanoma who have relapsed after treatment with chemotherapy or Interleukin-2 (IL-2). Pivanex is an investigational agent.
Interventions
- DRUG Pivanex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2004-01 |
| Est. Completion | 2004-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087477
The ClinicalTrials.gov registry entry for NCT00087477 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Titan Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pivanex is the first listed.
NCT00087477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00087477 about?
NCT00087477 is a clinical study titled "A Pilot Study of Pivanex in Patients With Malignant Melanoma". This pilot study will assess the safety and efficacy of Pivanex alone in patients with malignant melanoma who have relapsed after treatment with chemotherapy or Interleukin-2 (IL-2). Pivanex is an investigational agent.
What is the current status of trial NCT00087477?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2004-01. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00087477?
The interventions under investigation include: Pivanex (DRUG).
Who is sponsoring clinical trial NCT00087477?
This trial is sponsored by Titan Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.